![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The development of biological drugs blocking tumour necrosis factor-alpha (TNF-α) has had a dramatic impact on the treatment of inflammatory arthritis in recent years. Golimumab is a fully human monoclonal antibody which inhibits TNF-α. It is licensed for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. In this review we evaluate the results of phase III studies using golimumab and explore the place of golimumab in the treatment of these diseases.
Declaration of interest: Z Ash has received an unrestricted educational grant from Merck Sharpe & Dohme. She has also received conference expenses from Abbott, Chugai, and Merck Sharpe & Dohme and honoraria from Pfizer. P Emery has undertaken clinical trials and provided expert advice for Merck, Pfizer, Abbott, UCB, Roche, and Bristol-Myers Squibb.